We have located links that may give you full text access.
Journal Article
Research Support, Non-U.S. Gov't
Cadmium sulfide/graphitic carbon nitride heterostructure nanowire loading with a nickel hydroxide cocatalyst for highly efficient photocatalytic hydrogen production in water under visible light.
Nanoscale 2016 Februrary 29
Photocatalytic hydrogen production from water in a noble-metal-free system has attracted much attention in recent years. Herein we report on the use of core/shell cadmium sulfide/graphitic carbon nitride (CdS/g-C3N4) heterojunction nanorods modified by nickel hydroxide (Ni(OH)2) as a highly efficient photocatalyst for visible light-driven hydrogen production from water. Due to efficient separation of the photoexcited charge carriers in the CdS/g-C3N4 core/shell nanorods and the synergistic effect of Ni(OH)2, the optimal hydrogen evolution rate over Ni(OH)2-CdS/g-C3N4 is 115.18 μmol h(-1) mg(-1) under visible light irradiation (λ > 420 nm), which is ∼26 times higher than the CdS/g-C3N4 nanorod composite without Ni(OH)2 and ∼7 times better than the 0.5 wt% Pt-CdS/g-C3N4 nanorod composite. The apparent quantum efficiency is ∼16.7% at an excitation of 450 nm. During photocatalysis, no degradation of Ni(OH)2 was observed based on the XPS data, indicating that it is a robust cocatalyst. Moreover, the present photocatalyst showed excellent photocatalytic stability for hydrogen production and the turnover number (TON) reached ∼24,600 over 90 hours.
Full text links
Related Resources
Trending Papers
Autoimmune Hemolytic Anemias: Classifications, Pathophysiology, Diagnoses and Management.International Journal of Molecular Sciences 2024 April 13
Executive Summary: State-of-the-Art Review: Unintended Consequences: Risk of Opportunistic Infections Associated with Long-term Glucocorticoid Therapies in Adults.Clinical Infectious Diseases 2024 April 11
Clinical practice guidelines on the management of status epilepticus in adults: A systematic review.Epilepsia 2024 April 13
Finerenone: From the Mechanism of Action to Clinical Use in Kidney Disease.Pharmaceuticals 2024 March 27
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app